E.g., 03/29/2024
E.g., 03/29/2024
Title Category Credit Event date Pricesort descending
Advances in ADT Part II: A Guide for APPs Webcast (2023)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has created Advances in ADT: Part II: A Guide for APPs (2023), an educational offering to further update APPs on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This educational initiative is comprised of multiple formats, including a live course and on-demand webcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion. 
Refractory Overactive Bladder: How to Select 3rd Line Therapies and Optimize Outcomes Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Upon completion, participants will be familiar with third-line therapies available to treat refractory overactive bladder (OAB), including the pros and cons of each option, the current data regarding outcomes to facilitate proper patient counseling and optimal techniques to maximize the success of the various therapies. The case-based format will provide real-world scenarios by which to learn about the implementation of successful third-line options.
PARPi: Precision Medicine in Advanced Prostate Cancer Webcast (2023)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered.
The Changing Face of Advanced Prostate Cancer Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This is an ongoing course on advanced prostate cancer at the AUA Annual Meeting since 2012, and the changes over the last decade have been nothing less than breathtaking! In the early years, it was all about metastatic castrate-resistant prostate cancer (CRPC) with multiple new therapeutic advances starting in 2010, followed by abiraterone and enzalutamide and a focus on bone-targeted agents.
PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test Webcast (2023)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered.
AUA Guidelines on Advanced Prostate Cancer Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Incorporating the most updated AUA/ASTRO/SUO APC Guidelines, this course will be comprehensive in the approach to the diagnosis, management and outcomes of men with advanced, metastatic hormone sensitive prostate cancer (mHSPC) and castration-resistant prostate cancer (CRPC). The course will include germline testing, PSMA positron emission tomography imaging, and the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer.
PARPi: Management of Adverse Events Webcast (2024)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered.
Prostate Cancer Diagnosis: AUA Guidelines on Use of PSA Biomarkers, MRI and Biopsy Techniques Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Prostate cancer detection remains one of the most common and most controversial aspects of urological practice. In addition to the complexities around screening and use of PSA, the role of other biomarkers, biopsy techniques such as transperineal biopsy and MRI for targeted biopsy are evolving rapidly. This course is intended for urologists, advanced practice providers and trainees interested in using the most evidence-based methods for optimizing detection of clinically important prostate cancers, while improving patient experience and minimizing complications.
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Review of advanced and metastatic prostate, bladder and kidney cancer. Most recent treatment guidelines are reviewed along with the studies that support them. Different disease spaces in oncologic care are discussed, including the medications used to treat them, their mechanism, side effects and efficacy. Role of the advanced practice provider is discussed for each tumor type. Finally, cases are presented along with management options for audience participationACKNOWLEDGEMENTSIndependent educational grant support provided by:
How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 he learners will understand the following critical clinical aspects with regard to the clinical application of prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/CT scanning mode of action of PSMA-PET/CT: pitfalls of PSMA-PET/CT diagnostic accuracy depending on PSA, PSA double time, prostate cancer histology, application of PSMA-PET/CT to identify patients with intrapelvic nodal relapse who will benefit from local therapy such as salvage lymphadenectomy or stereotactic radiation therapy, application of PSMA-PET/CT to identify patients with organ-confined radiorecur
Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This case-based interactive course reviews the role of germline genetics in genitourinary (GU) cancers and how the identification of an alteration may impact precision oncology. We will provide a concise and comprehensive review of hereditary cancer genetics, and discuss genetic risk assessment, diagnosis and treatment for a range of hereditary kidney, urothelial carcinoma, prostate, and adrenal cancer syndromes. We will review current National Comprehensive Cancer Network® Guidelines for genetic evaluation of patients with kidney, upper tract, prostate, and adrenal cancers.
Building a Primary Palliative Care Model for Urology Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Building a Primary Palliative Care Model for Urology Webcast (2021) discusses aspects of palliative care that benefit patients, the urologist’s role and their collaboration with palliative care clinicians including:
Managing Toxicities of Checkpoint Inhibitors: A Urologist’s Guide Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Checkpoint inhibitors (CPIs) are increasingly being utilized in the treatment of urinary tract cancers, with several approvals in metastatic and now nonmetastatic spaces in bladder, kidney and prostate cancer. Urologists are encountering many patients on these therapies and have even started their own infusion programs with immuno -oncology drugs. This course will discuss and provide a structured, case-based approach to managing toxicities from CPIs within a busy urological practice.
Upper-Tract Urothelial Cancer Guidelines: An Interactive and Evidence-based Course Highlighting the Full Spectrum of Disease via Case Discussion and...
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will walk through the newly developed AUA Guidelines for Upper Tract Urothelial Cancer (UTUC) using an interactive discussion of complex cases with attendee involvement to enhance their knowledge of this challenging disease and provide a basis for practice improvement. Aspects such as optimizing initial workup and risk stratification, endoscopic techniques for biopsy and treatment, multidisciplinary management (e.g., coordinating with medical oncology, nephrology, genetic counseling) and nuances of surgical approaches will be stressed.
Diversity, Equity and Inclusion in Urology: What Do We Need to Know Webcast (2023)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 The course will review the statistics of underrepresented Blacks and Latinos in urology. Diversity, equity and inclusion initiatives are necessary for the advancement of urology. We will also include the LGBTQ population with respect to diversifying the urology workforce and identifying specific patient needs for the LGBTQ population. We will define the different types of racism and educate participants on the definition of racial and gender-based microaggression. We will identify tactics to address microaggressions in medicine.

Pages